| | Business Summary | | CITA
Biomedical,
Inc.,
through
its
wholly
owned
subsidiary,
CITA
Americas,
Inc.,
is
in
the
business
of
providing
the
technology,
information,
and
administrative
services
necessary
to
the
treatment
and
rapid
detoxification
of
persons
addicted
to
opiate
based
drugs
whether
natural
or
synthetic
(i.e.,
Methadone,
Heroin,
Codeine,
Demerol,
and
Percocet).
The
Company's
current
product
offering
consists
primarily
of
UROD,
which
stands
for
Ultra
Rapid
Opiate
Detoxification.
This
revolutionary
procedure
offers
successful
detoxification
from
heroin,
methadone
and
other
opiate
based
drugs
to
addicted
individuals
without
the
typical
elongated
painful
withdrawal
discomfort.
The
UROD
procedure
has
been
approved
as
an
accepted
treatment
method
by
the
American
Society
of
Addictive
Medicine. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | CITA
Biomedical,
which
is
a
development
stage
company,
through
CITA
Americas,
engages
in
the
investigation
and
treatment
of
addiction.
For
the
three
months
ended
3/31/01,
revenues
fell
40%
to
$57
thousand.
Net
loss
totalled
$655
thousand
up
from
$200
thousand.
Revenues
reflect
fewer
patients
being
treated
due
to
the
termination
of
a
number
of
license
agreements.
Higher
loss
also
reflects
increased
general
and
administrative
expenses
and
depreciation
and
amortization
expenses. | | More
from
Market Guide: Significant
Developments |
| | |
| Position | | Joseph Dunn, 49 | Chairman,
Pres, Chief Exec. and Financial Officer | | Michael Hinton, 53 | Sec. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/d/dtox.ob.gif)